Phase I Clinical Trial of Camptothecin-20-O-Propionate Hydrate (CZ48)
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Camptothecin (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Cao Pharmaceuticals
- 02 Oct 2017 Planned End Date changed from 1 Mar 2018 to 1 Jul 2018.
- 02 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 May 2018.
- 02 Oct 2017 Status changed from active, no longer recruiting to recruiting.